PCSK9-targeted siRNA
Inclisiran
Brand names: Leqvio
Adult dose
Dose: 284mg SC initially, then again at 3 months, then every 6 months
Route: SC
Frequency: q6 months (after loading)
Clinical pearls
- Primary hypercholesterolaemia/mixed dyslipidaemia not at LDL target on max-tolerated statin (NICE TA733)
- Twice-yearly dosing improves adherence vs PCSK9 mAbs
Contraindications
- Hypersensitivity
Side effects
- Injection site reactions
- Bronchitis-like symptoms
Monitoring
- Lipids
Reference: BNF; NICE TA733; ORION trials; https://bnf.nice.org.uk/drugs/inclisiran/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines